Investigators Identify Predictors of ESA Use in Nondialysis CKD
An analysis of contemporary ESA utilization among patients with anemia of nondialysis-dependent chronic kidney disease may help identify optimal candidates for treatment.
Anemias
Study: Roxadustat Effectively Treats Anemia Across CKD Stages
Roxadustat reduced the need for rescue therapy among patients with any stage of chronic kidney disease.
Anemia of Chronic Kidney Diseases Burden High Globally, Treatment Rates Low
Comorbidities and advanced CKD were prevalent among the approximately 275,000 patients with anemia of CKD from the international DISCOVER CKD cohort.
Heart Failure Hospitalizations Linked to Iron Deficiency in CKD
Early detection of iron status may improve cardiovascular risk assessment in patients with CKD, according to investigators.
RBC Transfusion Rates No Worse With Low Fixed-Dose Darbepoetin
Investigators sought to define an ESA dosing regimen that reduces the likelihood of transfusion while minimizing any potential cardiovascular risks.
Vadadustat NDA Submitted for Anemia Due to Chronic Kidney Disease
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
COVID-19 Antibodies Found in 1 in 5 US Blood Donations
Percentage of donations with antibodies has risen steadily over time, according to the Red Cross
Investigators ID Factors Affecting Predialysis Hemoglobin Control
Study findings reinforce the value of treating anemia during the transition to dialysis and illustrate the problem of ESA hyporesponsiveness.
World Kidney Day 2021: Living Well With Kidney Disease
The World Kidney Day Steering Committee has declared 2021 the year of “Living Well with Kidney Disease”.
Canagliflozin May Reduce Anemia Risk in Diabetic CKD
In the CREDENCE trial, patients receiving canagliflozin had reduced risks of initiating iron therapy and erythropoiesis-stimulating agents compared with patients receiving placebo.
-
Loading...
-
Loading...
Next post in Anemia
